AN2 THERAPEUTICS INC (ANTX) Stock Price, Quote, News and Overview
NASDAQ:ANTX - Nasdaq - US0373261058 - Common Stock - Currency: USD
ANTX Quote, Performance and Key Statistics
NASDAQ:ANTX (8/1/2025, 8:20:34 PM)
1.06
0 (0%)
The current stock price of ANTX is 1.06 USD. In the past month the price increased by 0.95%. In the past year, price decreased by -58.91%.
ANTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 55.4 | 722.49B | ||
| JNJ | JOHNSON & JOHNSON | 16.73 | 402.99B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.66 | 229.28B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.03 | 223.20B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 13.39 | 214.13B | ||
| MRK | MERCK & CO. INC. | 10.3 | 199.10B | ||
| PFE | PFIZER INC | 7.32 | 133.55B | ||
| SNY | SANOFI-ADR | 11.96 | 114.02B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.57 | 90.01B | ||
| GSK | GSK PLC-SPON ADR | 8.42 | 75.79B | ||
| ZTS | ZOETIS INC | 24.48 | 65.62B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 48.83 | 44.72B |
Related stock screener links
About ANTX
Company Profile
AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The company is headquartered in Menlo Park, California and currently employs 22 full-time employees. The company went IPO on 2022-03-25. The firm is focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. Its initial candidate is epetraborole, which is a potential once-daily, oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, which leads to irreversible lung damage and can be fatal. Epetraborole is designed to produce broad-spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. Epetraborole is an investigational, boron-containing, orally bioavailable, small molecule inhibitor of bacterial leucyl-tRNA synthetase (LeuRS), an enzyme that catalyzes the attachment of leucine to transfer RNA (tRNA), molecules, an essential step in protein synthesis.
Company Info
AN2 THERAPEUTICS INC
1800 El Camino Real, Suite D
Menlo Park CALIFORNIA 90501 US
CEO: Robert Corrigan
Employees: 41
Phone: 16503319090
AN2 THERAPEUTICS INC / ANTX FAQ
What is the stock price of AN2 THERAPEUTICS INC today?
The current stock price of ANTX is 1.06 USD.
What is the ticker symbol for AN2 THERAPEUTICS INC stock?
The exchange symbol of AN2 THERAPEUTICS INC is ANTX and it is listed on the Nasdaq exchange.
On which exchange is ANTX stock listed?
ANTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AN2 THERAPEUTICS INC stock?
8 analysts have analysed ANTX and the average price target is 1.7 USD. This implies a price increase of 60.38% is expected in the next year compared to the current price of 1.06. Check the AN2 THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AN2 THERAPEUTICS INC worth?
AN2 THERAPEUTICS INC (ANTX) has a market capitalization of 31.99M USD. This makes ANTX a Nano Cap stock.
How many employees does AN2 THERAPEUTICS INC have?
AN2 THERAPEUTICS INC (ANTX) currently has 41 employees.
What are the support and resistance levels for AN2 THERAPEUTICS INC (ANTX) stock?
AN2 THERAPEUTICS INC (ANTX) has a support level at 1.06 and a resistance level at 1.07. Check the full technical report for a detailed analysis of ANTX support and resistance levels.
Should I buy AN2 THERAPEUTICS INC (ANTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ANTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ANTX, evaluating the profitability, health, valuation and growth aspects
- AN2 THERAPEUTICS INC (ANTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AN2 THERAPEUTICS INC (ANTX) Sales and EPS estimates to see what analysts future expectations are.
- AN2 THERAPEUTICS INC (ANTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AN2 THERAPEUTICS INC (ANTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- AN2 THERAPEUTICS INC (ANTX) Stock Chart to make your own analysis
- AN2 THERAPEUTICS INC (ANTX) Latest news and press-releases to stay up to date.
Does AN2 THERAPEUTICS INC (ANTX) stock pay dividends?
ANTX does not pay a dividend.
When does AN2 THERAPEUTICS INC (ANTX) report earnings?
AN2 THERAPEUTICS INC (ANTX) will report earnings on 2025-08-07.
What is the Price/Earnings (PE) ratio of AN2 THERAPEUTICS INC (ANTX)?
AN2 THERAPEUTICS INC (ANTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.43).
What is the Short Interest ratio of AN2 THERAPEUTICS INC (ANTX) stock?
The outstanding short interest for AN2 THERAPEUTICS INC (ANTX) is 0.14% of its float. Check the ownership tab for more information on the ANTX short interest.
ANTX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ANTX. When comparing the yearly performance of all stocks, ANTX is a bad performer in the overall market: 94.11% of all stocks are doing better.
ANTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ANTX. While ANTX has a great health rating, there are worries on its profitability.
ANTX Financial Highlights
Over the last trailing twelve months ANTX reported a non-GAAP Earnings per Share(EPS) of -1.43. The EPS increased by 44.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -55.76% | ||
| ROE | -61.85% | ||
| Debt/Equity | 0 |
ANTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 48% to ANTX. The Buy consensus is the average rating of analysts ratings from 8 analysts.